ATE408693T1 - Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff - Google Patents

Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff

Info

Publication number
ATE408693T1
ATE408693T1 AT00941614T AT00941614T ATE408693T1 AT E408693 T1 ATE408693 T1 AT E408693T1 AT 00941614 T AT00941614 T AT 00941614T AT 00941614 T AT00941614 T AT 00941614T AT E408693 T1 ATE408693 T1 AT E408693T1
Authority
AT
Austria
Prior art keywords
piv
vaccine
genome
parainfluenza virus
bovine
Prior art date
Application number
AT00941614T
Other languages
German (de)
English (en)
Inventor
Alexander Schmidt
Mario Skiadopoulos
Peter L Collins
Brian Murphy
Jane Bailly
Anna Durbin
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE408693T1 publication Critical patent/ATE408693T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AT00941614T 1999-07-09 2000-06-16 Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff ATE408693T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14313499P 1999-07-09 1999-07-09

Publications (1)

Publication Number Publication Date
ATE408693T1 true ATE408693T1 (de) 2008-10-15

Family

ID=22502741

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00941614T ATE408693T1 (de) 1999-07-09 2000-06-16 Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff

Country Status (12)

Country Link
EP (3) EP1194564B1 (enExample)
JP (1) JP4813711B2 (enExample)
KR (1) KR100940776B1 (enExample)
CN (2) CN101392239A (enExample)
AT (1) ATE408693T1 (enExample)
BR (1) BR0013190A (enExample)
CA (1) CA2378661A1 (enExample)
DE (1) DE60040289D1 (enExample)
ES (1) ES2312347T3 (enExample)
IL (2) IL147167A0 (enExample)
MX (1) MXPA01013302A (enExample)
WO (1) WO2001004320A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192593B2 (en) 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
EP1179054A2 (en) * 1999-12-10 2002-02-13 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Use of recombinant parainfluenza viruses (pivs) as vectors to protect against infection and disease caused by piv and other human pathogens
US6764685B1 (en) * 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
WO2002002605A2 (en) * 2000-07-05 2002-01-10 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
DK1351981T3 (da) 2001-01-19 2012-11-26 Vironovative Bv Et virus, der forårsager luftvejssygdom hos modtagelige pattedyr
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
ATE509097T1 (de) 2001-11-21 2011-05-15 Us Health Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
TWI344991B (en) 2002-02-21 2011-07-11 Medimmune Vaccines Inc Metapneumovirus strains as vaccine formulations and as vectors for expression of heterologous antigenic sequences
US7820181B2 (en) 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP2007524372A (ja) 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 組換えヒトメタニューモウイルスおよびその使用
CN101410519B (zh) 2003-04-25 2013-04-24 免疫医疗有限责任公司 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法
CA2523657A1 (en) * 2003-04-25 2005-03-31 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
WO2004113517A2 (en) 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
CN107818197B (zh) * 2017-09-15 2021-05-25 南京航空航天大学 一种基于piv技术的超声速翼型的测力方法和装置
GB201816873D0 (en) * 2018-10-17 2018-11-28 Imperial Innovations Ltd Fusion protein
CN113322241B (zh) * 2021-05-14 2023-06-13 金宇保灵生物药品有限公司 一种牛副流感病毒3型病毒株bpiv3-nm及其应用
CN116676275B (zh) * 2023-03-17 2024-06-07 北京赛尔富森生物科技有限公司 A基因型嵌合腮腺炎病毒株和制备方法及用途
AU2024380679A1 (en) 2023-11-17 2026-07-02 Sanofi Vaccines US Inc. Trehalose vaccine formulation
CN118909958B (zh) * 2024-07-25 2025-02-07 中国兽医药品监察所 一株牛副流感病毒3型np蛋白杂交瘤细胞株及单抗和在检测抗原中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
EP0780475B2 (en) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Process for the production of infectious negative-strand RNA viruses
US6165774A (en) * 1995-09-22 2000-12-26 Connaught Laboratories Limited Parainfluenza virus glycoproteins and vaccines
US5869036A (en) * 1995-12-08 1999-02-09 St. Louis University Live attenuated vaccines based on CP45 HPIV-3 strain and method to ensure attenuation in such vaccine
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
DE69842165D1 (de) * 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen

Also Published As

Publication number Publication date
IL147167A (en) 2010-06-16
WO2001004320A1 (en) 2001-01-18
KR100940776B1 (ko) 2010-02-11
EP2019140A2 (en) 2009-01-28
EP1194564A1 (en) 2002-04-10
EP2019141A2 (en) 2009-01-28
CN100402651C (zh) 2008-07-16
JP2003504064A (ja) 2003-02-04
JP4813711B2 (ja) 2011-11-09
IL147167A0 (en) 2002-08-14
CN1369011A (zh) 2002-09-11
KR20020022768A (ko) 2002-03-27
DE60040289D1 (de) 2008-10-30
EP2019140A3 (en) 2009-02-04
EP1194564B1 (en) 2008-09-17
BR0013190A (pt) 2002-07-16
EP2019141A3 (en) 2009-02-04
CA2378661A1 (en) 2001-01-18
CN101392239A (zh) 2009-03-25
MXPA01013302A (es) 2004-03-10
ES2312347T3 (es) 2009-03-01

Similar Documents

Publication Publication Date Title
DE60040289D1 (de) Attenuiertes human-bovines chimärisches parainfluenzavirus als impfstoff
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
ATE509097T1 (de) Gewinnung von rekombinantem menschlichem parainfluenzavirus typ 1 (hpivi) aus cdna
DK0804584T3 (da) Sekvenser af hepatitis C virus genotype 7 og deres anvendelse som profylaktiske, terapeutiske og diagnostiske midler
DK1542732T3 (da) Fusionsproteiner af Mycobacterium tuberculosis
ATE417097T1 (de) Rekombinantes respiratorische synzytialvirus expressionssystem und impfstoffe
DE69535680D1 (de) Sekretierte, virale cmv proteine verwendbar als impfstoffe und diagnostika
ATE366314T1 (de) Infektioese rna virus-klone, vakzine und davon abgeleitete diagnostische assays
ATE507312T1 (de) Nachweis und typisierung das hepatitis c virus (hcv) mittels 5'utr und ns5 nukleinsäuresequenzen
BR9807873A (pt) Vacinas de flavivìrus quiméricos
DE69206631D1 (de) Impfstoff gegen das Fortpflanzungs- und Atmungssyndrom bei Schweinen (PRRS) und Diagnose.
ATE387914T1 (de) Verfahren zur in vitro-diagnose von infektionen durch schweinecircovirus vom typ ii und diagnostische reagenzien
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
EP1572947A4 (en) RECOVERY OF RECOMBINANT HUMAN PARAIN FLUENZA VIRUS TYPE 2 (HPIV2) FROM cDNA AND USE OF RECOMBINANT HPIV2 IN IMMUNOGENIC COMPOSITIONS AND AS VECTORS FOR THE RECOVERY OF IMMUNE REACTIONS AGAINST PIV AND OTHER HUMAN DISEASES
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
DK513388D0 (da) Peptider med immunologiske egenskaber svarende til hiv-2 virus, nucleotidsekvenser, der koder for saadanne peptider, antigene og immunogene midler indeholdende saadanne peptider samt fremgangsmaade og kit til in vitro diagnose af hiv-2
AU2001290178A1 (en) A hepatitis c virus non-structural ns3/4a fusion gene
ATE461283T1 (de) Neue vollständige genomische rna des japanenzephalitis-virus, infektiöse jev cdna daraus und deren verwendung
ATE267256T1 (de) Hepatis e-virus antigene und dessen verwendungen
LU91149I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et d'antigène de surface recombinant du virus d l'hépatite B(protéine S).
ATE332712T1 (de) Nukleinsaüre- und aminosaürensequenzen von infectious salmon anaemia virus, und deren verwendung als impfstoffe
WO2002002605A3 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
DE60136811D1 (de) Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren
CA2286399A1 (en) Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties
REN Ceased due to non-payment of the annual fee